Aprepitant

Aprepitant is a neurokinin-1 (NK1) receptor antagonist used as an antiemetic. Chemically it is built on a morpholine core carrying fluorinated aromatic groups and a triazolinone ring. By blocking the NK1 receptor it interrupts one of the body's key vomiting signals, acting through a different pathway than older antiemetics.

The drug was discovered and developed by Merck, growing out of a program to optimize potent, orally active NK1 antagonists; one key medicinal-chemistry step produced the long-acting morpholine compound that became aprepitant ^[4]. It was approved in the United States and the European Union in 2003. An intravenous prodrug form, fosaprepitant, which the body converts to aprepitant, was later introduced for situations where oral dosing is impractical.

Aprepitant is used chiefly to prevent chemotherapy-induced nausea and vomiting, both the acute phase during and shortly after treatment and the delayed phase in the following days, and it is also used for postoperative nausea and vomiting. It is typically combined with a serotonin 5-HT3 receptor antagonist and a corticosteroid such as dexamethasone. Pooled analyses of large phase III trials showed that adding aprepitant to this standard regimen substantially increased the proportion of patients with no vomiting after highly emetogenic chemotherapy ^[2].

Brain-imaging studies using positron emission tomography confirmed that oral aprepitant occupies central NK1 receptors in a dose-related way, helping establish the doses needed for a clinical effect ^[1]. Common side effects include tiredness, loss of appetite, diarrhea, hiccups, and, less often, changes in blood counts or allergic reactions. Aprepitant can interact with other drugs because it affects certain liver enzymes that metabolize medications.

Aprepitant is a prescription medicine available in oral form, with fosaprepitant available for intravenous use. It is included on lists of important supportive-care medicines for cancer treatment because of its role in making chemotherapy more tolerable.

Aprepitant is a prescription medicine and is generally well tolerated. Common side effects include fatigue, hiccups, constipation or diarrhea, headache, reduced appetite, and mild rises in liver enzymes. Its main practical concern is drug interactions through CYP3A4; it can lower the effectiveness of oral contraceptives, so a backup method is advised, can change the response to warfarin and lower the INR, and it changes how much dexamethasone is needed. It is not a stand-alone treatment and is always used as part of an antiemetic regimen timed around chemotherapy.

Aprepitant is a moderate CYP3A4 inhibitor and a weak CYP2C9 inducer, so it moves other drugs more than other drugs move it.

Pimozide is contraindicated: it depends on CYP3A4, and raised concentrations carry QT prolongation and torsade de pointes. Corticosteroids cleared by the same route accumulate, with oral dexamethasone exposure roughly doubling and methylprednisolone rising as well, which is why antiemetic regimens quietly account for it. Midazolam and other CYP3A4 dependent benzodiazepines are similarly prolonged.

The CYP2C9 induction runs the other way and is easy to miss because it is delayed. Warfarin is cleared faster, INR drifts down, and the trough typically lands seven to ten days after a three day aprepitant course, well after the drug itself has gone. Ethinyl estradiol exposure also falls, and contraceptive efficacy can stay reduced for about four weeks after the last dose.

Aprepitant's own concentrations rise substantially with strong CYP3A4 inhibitors such as ketoconazole or ritonavir and collapse with rifampin, phenytoin or carbamazepine, where loss of antiemetic effect is the practical consequence.

Checking a whole stack? Run it through interactions + stacks.

Aprepitant grew out of research into substance P and its neurokinin-1 receptor, a signaling system implicated in the vomiting reflex, pain, and mood. Merck scientists pursued a brain-penetrant NK1 antagonist across the 1990s, and aprepitant became the first drug of its class to reach the market when the United States Food and Drug Administration approved it in March 2003 for prevention of chemotherapy-induced nausea and vomiting. Its approval validated decades of work on the tachykinin system and addressed the delayed-phase nausea that older serotonin-based antiemetics handled poorly. An intravenous prodrug form, fosaprepitant, was later introduced to allow single-dose administration, and the indication was extended to postoperative nausea and vomiting.

Aprepitant is widely credited with transforming the management of chemotherapy-induced nausea, especially the stubborn delayed phase that begins a day or more after treatment. Oncology guidelines routinely recommend it as part of a three-drug regimen alongside a 5-HT3 antagonist and a corticosteroid, and patients often describe meaningful relief that lets them complete difficult chemotherapy cycles. It is generally well tolerated, with fatigue and hiccups among the more common complaints. Clinicians appreciate its distinct mechanism, which adds protection on top of older agents, while remaining mindful of its interactions through the liver enzyme CYP3A4.